Leerink Partnrs Estimates Immunocore Q1 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Immunocore in a report released on Wednesday, February 26th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of ($0.48) for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s FY2025 earnings at ($1.78) EPS.

IMCR has been the subject of several other research reports. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Friday. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Trading Down 0.7 %

NASDAQ IMCR opened at $29.37 on Friday. Immunocore has a one year low of $27.69 and a one year high of $72.05. The company’s 50 day moving average price is $30.08 and its 200 day moving average price is $31.89. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -30.92 and a beta of 0.77.

Institutional Investors Weigh In On Immunocore

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Primecap Management Co. CA lifted its holdings in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after purchasing an additional 520,950 shares during the last quarter. State Street Corp increased its position in Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after buying an additional 29,897 shares during the period. Principal Financial Group Inc. increased its position in Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after buying an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after buying an additional 27,598 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after buying an additional 91,033 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.